Population Pharmacokinetics and Exposure-Safety of Lipophilic Conjugates Prodrug DP-VPA in Healthy Chinese Subjects for Dose Regime Exploring

Yi Li,Huizhong Zhan,Jufang Wu,Jicheng Yu,Guoying Cao,Xiaojie Wu,Beining Guo,Xiaofen Liu,Yaxin Fan,Jiali Hu,Xin Li,Hailan Wu,Yu Wang,Yuancheng Chen,Xiaoyong Xu,Peimin Yu,Jing Zhang
DOI: https://doi.org/10.1016/j.ejpb.2023.04.023
IF: 5.589
2023-05-05
European Journal of Pharmaceutics and Biopharmaceutics
Abstract:Phospholipid-valproic acid (DP-VPA) is a prodrug for treating epilepsy. The present study explored the pharmacokinetics (PK) and exposure safety of DP-VPA to provide a basis for future studies exploring the safe dosage and therapeutic strategies for epilepsy. The study included a randomized placebo-controlled dose-escalation tolerance evaluation trial and a randomized triple crossover food-effect trial in healthy Chinese volunteers. A population pharmacokinetic (PopPK) model was established to analyze the PK of DP-VPA and active metabolite VPA. The exposure safety was assessed with the adverse drug reaction (ADR) in CNS. The PopPK of DP-VPA and metabolite VPA fitted a two-compartment model coupling one-compartment with Michaelis-Menten metabolite kinetics and first-order elimination. The absorption processes after single oral administration of DP-VPA tablet demonstrated nonlinear characteristics, including 0-order kinetic phase and time-dependent phase fitting Weibull distribution. The final model indicated that the DP-VPA PK was significantly affected by dosage and food. The exposure-safety relationship demonstrated a generalized linear regression; mild/moderate ADRs occurred in some subjects with 600 mg and all subjects with 1500 mg of DP-VPA, and no severe ADRs were reported up to 2400 mg. In conclusion, the study established a PopPK model describing the processing of DP-VPA and VPA in healthy Chinese subjects. DP-VPA showed good tolerance after a single dose of 600–2400 mg with nonlinear PK and was affected by dosage and food. Based on the association between neurological ADRs and higher exposure to DP-VPA by exposure-safety analysis, 900–1200 mg was recommended for subsequent study of safety and clinical effectiveness.
pharmacology & pharmacy
What problem does this paper attempt to address?